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Pattern of systemic antibiotic use and potential drug interactions: evaluations through a
point prevalence study in Ankara University Hospitals
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Background/aim: Most of the hospitalized patients are on a number of drugs for comorbidities and/or to prevent nosocomial infections.
This necessitates a careful consideration of drug interactions not only to avoid possible toxicities but also to reach the highest efficiency
with drug treatment. We aimed to investigate drug interactions related to systemic antibiotic use and compare three different databases
to check for drug interactions while characterizing the main differences between medical and surgical departments.
Materials and methods: This point prevalence study covered data on 927 orders for patients hospitalized between June 3 and 10, 2018
in Ankara University Hospitals. Systemic antibiotic use and related drug interactions were documented using UptoDate, Drugs, and
Medscape and comparisons between the departments of medical and surgical sciences were made.
Results: The number of orders, or the number of drugs or antibiotics per order were not different between the medical and surgical
sciences departments. A total of 1335 antibiotic-related drug interactions of all levels were reported by one, two, or all three databases.
UptoDate reported all common and major interactions. Pantoprazole was the most commonly prescribed drug and appeared in 63%
of all orders. Among 75 different molecules, ceftriaxone and meropenem were the two most prescribed antibiotics by the surgical and
medical departments, respectively.
Conclusion: A dramatic variance existed amongst antibiotics prescribed by different departments. This indicated the requirement
for a centralized role of an infectious diseases specialist. Especially for the hospitalized patient, prophylactic coverage with at least
one antibiotic brought about a number of drug interactions. A precise evaluation of orders in terms of drug interactions by a clinical
pharmacist (currently none on duty) will reduce possible drug-related hazards.
Key words: Antibacterial agents, drug interactions, pharmacist

1. Introduction
In addition to lack of new antibiotics, the well-recognized
danger of resistance to available drugs necessitates rational
use of antibiotics in both hospital and outpatient settings.
A retrospective study by Centers for Disease Control and
Prevention (CDC) reported that between 2006 and 2012,
55% of patients used at least one dose of an antibiotic
during their hospital stay [1].
Moreover, community-acquired and nosocomial
infections require multidrug treatment in most
hospitalized patients. The clinicians cannot take the risk
not reaching the maximum efficiency of the antibiotic
drug. This becomes even more pronounced when socalled “last-resort” antibiotics are used. Considering that
most of the hospitalized patients are on a number of drugs
for comorbidities, possible drug interactions become

one of the crucial aspects of therapy that the clinician is
forced to take into account when planning the treatment.
One problem for this kind of assessment in developing
countries is the affordability of drug databases that are
integrated into an interaction tool. In addition, there is
little agreement among commonly used drug interaction
databases and a gold-standard reference is absent [2].
For example, when mixed together in solution in vitro,
extended spectrum penicillins result in an inactivation
of aminoglycosides [3–6]. A similar inactivation seems
to be present in vivo in patients with renal dysfunction
and results in a decrease in the half-life of aminoglycoside
[7–9]. Hence, the web-based interaction tool UptoDate
prompts the clinician to consider therapy modification
(Risk Level D) based on references 3–9 when the
possible interaction between piperacillin and systemic
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gentamicin were analyzed [10]. Prescribing information
of a piperacillin-containing drug also reports both in vivo
and in vitro interactions [11]. On the other hand, another
commonly used tool for interactions, Medscape reports
that piperacillin increases the effects of gentamicin by
pharmacodynamic synergism [12].
Interaction between drugs may also result in severe
clinical cases such as coagulation abnormalities, organ
dysfunctions, or electrolyte imbalances simply due to
additive adverse effects. Concurrent use of cotrimoxazole
and any inhibitor of the renin-angiotensin-aldosterone
system is expected to increase the risk of hyperkalemia,
an interaction unequivocally documented in many case
reports, as well as a population-based study that linked
this combination to sudden death in older patients due to
unrecognized hyperkalemia [13]. Thus, a thorough review
of the available evidence is required when planning drug
treatment to achieve the maximum efficacy while avoiding
interaction-related treatment failure or adverse effects.
Studies show that both the quantity and selection of
antibiotics still vary dramatically even among hospitals
within a country [14] and this is true for Turkey. In
addition, Turkey is one of the countries with the highest
antibiotic consumption per capita and suffers widespread
antimicrobial resistance [15,16].
We aimed to investigate potential drug interactions
related to systemic antibiotic use and compare three
different databases in documenting these interactions. We
also compared the patterns of antibiotic use between the
medical and surgical departments of Ankara University
Hospitals through this prevalence study.

and Medscape. All three databases have web-based tools
to evaluate drug interactions based on the information
collected by their expert panels. UptoDate and Drugs,
but not Medscape, provide the references for the reported
interactions as well. They are also slightly different in terms
of the levels of reported interactions. UptoDate reports
drug interactions on five levels: X (avoid combination), D
(consider therapy modification), C (monitor therapy), B
(no action needed), and A (no known interaction). Drugs
reports drug interaction on three main levels: major
(subdivided into “contraindicated” and “monitor closely”);
moderate, and minor. Medscape reports four levels of
drug interactions: contraindicated, serious-use alternative,
monitor closely, and minor.
Some characteristics related to drug usage were
compared between departments of medical and surgical
sciences. Next, the efficiency of databases was compared
for reporting common, as well as major interactions. To
do this, all interactions of all levels that include at least
one antibiotic were documented and unique interactions
were identified. Each database was evaluated in two ways:
1. documenting the interaction that is reported by all three
databases, 2. documenting a major interaction that is
reported by all three databases.
The difference between the medical and surgical
departments was analyzed using Student’s t-test when data
expressed as mean ± SEM were compared. Chi-square
test of probability was utilized when comparing medical
and surgical departments for empiric, prophylactic, and
targeted use of antibiotics. A level of probability of P <
0.05 was deemed to constitute the threshold for statistical
significance.

2. Materials and methods
This study was conducted at Ankara University Hospitals
that have a total number of 2000 beds over two campuses
and approach an occupancy level of nearly 95% at all times.
It was approved by the Ethics Committee of the Faculty of
Medicine of Ankara University (28 May 2018, 0958818)
with a waiver of informed consent due to the retrospective
nature of the study. The data were collected from patients
≥18 years that were hospitalized between June 3 and June
10, 2018. All patients who received at least one systemic
antimicrobial (antibacterial, antifungal, or antiviral) drug
were included. Demographic data, preexisting medical
conditions, and drug regimens were collected via the
patient medical record system of Ankara University
Hospitals, Avicenna. Antibiotic use was categorized as
empiric, prophylactic, and targeted. Empiric use was
against an anticipated cause of the infection whereas
targeted or definitive use was directed against a known
pathogen. Prophylactic use is defined as cases where a clear
indication was missing. Potential drug interactions were
analyzed using three different databases, UptoDate, Drugs,

3. Results
A total of 927 orders were collected during the study
period. However, only the orders that included at least
one systemic antibiotic were evaluated. A total of 907
patients had at least one antibiotic in their orders. Of these
patients, 498 were in medical and 409 in surgical clinics.
Demographic data and comorbidities are shown in Table
1. Briefly, the median age was 58 years (range 18–97 years)
and 481 (53%) patients were female. The most common
underlying medical condition was hypertension (312
(34%)).
The main characteristics of drug use are shown in Table
2. The total number of orders, all drugs, and antibiotics
were similar between surgical and medical clinics. The
percentage of antibiotics to all drugs was not different
between the clinics of medical and surgical departments.
Somewhat surprisingly, the mean number of orders
that included at least one antibiotic was nearly the same
between medical and surgical clinics.
A more detailed analysis of drug use is shown in
Table 3. The most commonly prescribed drug in all
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Table 1. Demographic data and comorbidities.
Parameter

Value

Number of patients
Medical Clinics
Surgical Clinics

498
409

Age, median (range)

58 (18–97)

Female/male

481/426

Comorbidities, number (%)
Hypertension
Diabetes
Malignancy
Renal insufficiency
Liver failure
Other
(Heart failure, coronary artery disease, benign
prostate hypertrophy, psychiatric disease,
neurologic disease, chronic obstructive
pulmonary disease, transplantation)

312 (34)
222 (24)
232 (26)
73 (8)
39 (4)
544 (60)

clinics was a proton pump inhibitor (PPI), pantoprazole,
which appeared in more than 60% of all orders. The most
prescribed antibiotic in the orders from medical clinics
was meropenem and appeared in 12% of these orders. This
drug was prescribed to only 5% of surgical clinics’ patients.
Ceftriaxone was the most common antibiotic in the orders
from surgical clinics. Ceftriaxone was prescribed to 17%

of patients in surgical clinics and to only 5% of patients in
medical clinics.
Types of antibiotic treatment are summarized in
Table 4. Medical and surgical clinics were similar in
empiric usage of antibiotics. Expectedly, when compared
to medical clinics, surgical clinics primarily prescribe
antibiotics, namely ceftriaxone and metronidazole, for
prophylaxis. In fact, prophylactic use of metronidanazole
appeared in 13% of orders from surgical clinics. On the
other hand, targeted utilization of antibiotics was higher
in medical clinics compared to surgical clinics as opposed
to our predictions.
A total of 1335 antibiotic-related drug interactions of
all levels were reported by one, two, or all three databases.
Interactions reported by each database were compared
between medical and surgical clinics. First, interactions
of all levels per order were compared using each database
for medical and surgical clinics. Next, these clinics were
compared in terms of interactions of a similar rank of a
particular database per order. For example, UptoDate
reports the highest level of interactions with “X (avoid
combination)” and the second level of interactions with
“D (consider therapy modification)” whereas the highest
two levels for Drugs are “major-contraindicated” and
“monitor closely”. Neither all interactions nor interactions
of equal level were different between medical and surgical
departments (results not shown).
Of the 1335 interactions, 552 were unique, meaning
that one particular interaction between antibiotic A and
drug D was documented ≥1 and reported by one, two,

Table 2. Main characteristics of drug use.
Parameter

Medical clinics,
Mean ± SEM

Surgical clinics,
Mean ± SEM

P

Number of orders

25 ± 4

26 ± 5

0.92

Number of orders that include an antibiotic

13 ± 2

18 ± 4

0.31

Number of all drugs

249 ± 39

180 ± 36

0.22

(Antibiotic/order) %

11.80

15.13

0.09

Table 3. Drug use, detailed analysis.
				
Medical clinics

Surgical clinics

Most commonly used drug, count

Pantoprazole, 325

Pantoprazole, 255

Two most frequently prescribed antibiotics, count

Meropenem, 62

Ceftriaxone, 72

Number of antibiotics (%)
Prophylaxis
Empiric
Targeted

65 (15)
121 (28)
245 (57)

159 (40)
126 (31)
114 (29)
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Table 4. Type of antibiotic treatment.
Type of therapy

Medical clinics (%)

Surgical clinics (%)

P

Prophylaxis

4.47

33.45

0.005

Empiric

37.80

30.66

0.08

Targeted

57.72

45.94

0.005

or all three databases. The distribution of these unique
interactions as reported by the databases is shown in Figure
1. In the figure, the total count of interactions is 1335. A
unique interaction is defined as one particular interaction
between antibiotic A and drug D that was documented at
least once, but counted as 1 no matter how many times it
appeared.
UptoDate reported 296, Drugs reported 346, and
Medscape reported 329 of these unique interactions. One
hundred fifty-nine of these unique 552 interactions were
reported by all databases.
The highest level of interaction is reported with X,
major-contraindicated, and contraindicated by UptoDate,
Drugs, and Medscape, respectively. The distribution of
the highest level of unique interactions as reported by
the databases is shown in Figure 2. UptoDate reported
24, Drugs reported 73, and Medscape reported 72 of the
highest level of unique interactions. Seven interactions in
this category were reported by all databases. Highest level
of interaction is reported with X, major-contraindicated,
and contraindicated by UptoDate, Drugs, and Medscape,
respectively. UptoDate reported 24 (9+7+6+2), Drugs
reported 73 (37+23+7+6), and Medscape reported 72
(40+23+7+2) of these highest level of unique interactions.
Seven interactions in this category were reported by all
databases.
4. Discussion
Extensive research and accumulating evidence raised
awareness in current medical practice of drug interactions
and their possible outcomes. Particularly in those
patients with comorbidities treated with multiple drugs,
a detailed interrogation of possible drug interactions
must be acknowledged as a priority. The consequences
of drug interactions of all levels concerns health care
professionals in every setting. However, reduction in
plasma level due to excessive metabolism or increase to
toxic concentrations are only two examples that cannot
be tolerated in the treatment of infectious diseases. This
study was primarily undertaken to evaluate the main
characteristics of antibiotic use and how these affect
possible drug interactions related thereto. A specific
emphasis was put on comparing surgical and medical
departments in order to understand the variation in
practice and identify the current problems. A nationwide
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antibiotic restriction program (NARP) was released in
2003 in Turkey (Official Gazette of the Republic of Turkey,
Feb 1, 2003). This compulsory program aimed to reduce
hospital antimicrobial use by mandating preauthorization
from an infectious disease specialist for the use of some
several broad-spectrum antibiotics. However, most of the
antibiotic decision-making in hospitals takes place with no
direct input from an infectious disease specialist mainly
due to the insufficient number of experts in hospitals.
Hence, rates of resistance indicate that antimicrobial
consumption is still not as strictly controlled as required
by NARP at the national level and this holds true for
Ankara University Hospitals [17].
One of the main findings of this study was the
prophylactic use of broad-spectrum antibiotics in surgical
clinics as documented by the lack of a definitive indication
as opposed to medical clinics where the antibiotics were
prescribed as part of a targeted therapy. The propensity in
surgical clinics in our study was to prescribe ceftriaxone and
metronidazole. A similar recent study reported that initial
treatment started with metronidazole and cefuroxime
in surgical clinics and mostly stepped up to intravenous
broad-spectrum agents [18]. The authors confirmed
surgical prophylaxis or surgical site infection as the targets
of initial antibiotic use [19,20]. Our study was designed
to measure the characteristics of initial prescription of
antibiotics and to correlate this information with possible
drug interactions. Therefore, a detailed analysis related to
antibiotic use such as antibiotic exposure days or duration
of treatment was not conducted.
Using a slightly different approach, another study from
Turkey reported the frequency and potential drug–drug
interactions in five different hospitals. Here, the authors
showed that more than 25% of all interactions were
associated with antimicrobials. In addition, the number of
prescribed antimicrobials, as well as prescribed drugs and
hospitalization in the university hospital were independent
risk factors for developing drug interactions [21].
Both meropenem and ceftriaxone, two of the most
prescribed antibiotics by medical and surgical clinics,
respectively, have a unique status in NARP. Meropenem
requires preauthorization from an infectious disease
specialist. Ceftriaxone treatment may be initiated by any
specialist if the treatment is limited to 72 h and extended
use beyond the 72 h limit also requires authorization by
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UptoDate

Drugs
97

58
68

159

11

32

127

Medscape

Figure 1. Venn diagram of the distribution of unique interactions as reported
by UptoDate, Drugs, and Medscape.

UptoDate

Drugs

37

6
9

7

2

23

40

Medscape

Figure 2. Venn diagram of the highest level of unique interactions as reported by
UptoDate, Drugs, and Medscape.

an infectious disease specialist. In other words, other
specialists are comparatively less limited when prescribing
a rather broad-spectrum antibiotic, ceftriaxone. This
information indicates that antibiotic stewardship
interventions targeting surgical clinics need to go beyond

prophylaxis and require a stronger input from infectious
diseases specialists.
Another important finding of this study is that a PPI,
pantoprazole, appeared in 63% of all orders in both medical
and surgical clinics without a clear indication. Overuse
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of PPIs has repeatedly been reported by many studies
[22,23]. Despite some controversy, evidence has linked
PPI use with serious adverse effects such as increased risk
of Clostridium difficile (C. difficile) infections, communityacquired and hospital-acquired pneumonia, and
andosteoporotic fractures [24–26]. A recent metaanalysis
and systematic review of 14 studies showed that antibiotic
exposure and PPI use appeared to be the most important
risk factors associated with C. difficile infection in children
[27]. Apart from these serious outcomes, PPIs carry a
considerable potential for drug interactions not only based
on their potential to alter gastric pH but also because of
their different affinities for some of the drug-metabolizing
enzymes in the liver [28,29]. The number of orders that
included a PPI was not different between medical and
surgical clinics. However, a high prescription rate still
indicated that all health care professionals should remain
vigilant and continue judicious use of not only antibiotics,
but also PPIs in hospitalized patients.
One of the main questions of this study was whether
differences in antibiotic use would affect the possible drug
interactions as reported by the web-based interaction
tools. The immediate challenge was the observation
that these tools were not consistent with the potential
interactions that they reported. The clinicians often suffer
lack of sufficient time in planning a treatment, which does
not allow them to check all available resources for possible
drug interactions. We, therefore, felt the need to identify
the database that is the most efficient in reporting drug
interactions so that this particular database could be
preferred in the future to check for possible interactions.
Two parameters were utilized: 1. How efficient is a database
in reporting the interactions that were also reported by

other databases? 2. How efficient is a database in reporting
the highest level of interactions that were also reported by
other databases?
UptoDate was the most efficient in reporting common
interactions (159/296) compared to Medscape (159/329)
and Drugs (159/346). The efficiency of UptoDate in
reporting the highest level of interactions was also the
greatest (7/24) compared to Medscape (7/72) and Drugs
(7/73). Thus, UptoDate appeared to be somewhat stronger
in reporting possible drug interactions.
This study has some limitations such as the lack of
confirmation of the reported drug interactions. This
is primarily because of the design, where no follow up
was planned. Instead, whether the basic characteristics
of the initiation of antibiotic use were different between
medical and surgical clinics was the main question of this
study. However, any possible interaction of a high rank
regardless of the database was immediately communicated
with the related clinic during the study. Again, whether or
not drug regimen was altered by the clinic based on our
recommendation was not tracked.
We believe that the presence of additional health care
professionals, such as a trained clinical pharmacist, at the
initiation of therapy and perhaps during the course of
hospital stay will provide an additional check-point and
help to minimize possible drug interactions and other
drug-related issues.
Informed consent and ethical approval
The study was approved by the Ethics Committee of
the Faculty of Medicine of Ankara University (Date:
28.05.2018, Number: 09-588-18) with a waiver of informed
consent due to the retrospective nature of the study.
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